NASDAQ · TYRA
Tyra Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for TYRA: Nov 4, 2026
Tyra Biosciences, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 8 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.66. The reported EPS for the same quarter last year was $-0.5.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.66 | $-0.47 | $-0.76 | 8 |
| Dec 2026 | $-0.64 | $-0.50 | $-0.77 | 7 |
| Mar 2027 | $-0.60 | $-0.51 | $-0.73 | 5 |
| Jun 2027 | $-0.63 | $-0.54 | $-0.75 | 5 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest · Fintel- Zacks · Oct 14, 8:35 AM EDTHere's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 WeeksTyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- RTTNews · Sep 14, 2:17 PM EDTBiotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains(RTTNews) – Several biotech stocks were in focus Monday, including Tyra Biosciences following a $400 million stock and warrant offering to advance its dabogratinib 3×3 strategy; Nasus Pharma after FDA clearance of its IND for intranasal epinephrine NS002; Bionano Genomics followi
- RTTNews · Sep 14, 9:24 AM EDTTyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3×3(RTTNews) – Tyra Biosciences, Inc. (TYRA), a clinical-stage biotechnology company focused on precision medicines targeting fibroblast growth factor receptor (FGFR) biology, on Monday announced the pricing of a $400 million underwritten offering of common stock and pre-funded warr
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- RTTNews · Sep 9, 8:52 AM EDTTyra Biosciences Reports Positive SURF302 Results; Plans Phase 3 In LG IR NMIBC(RTTNews) – Tyra Biosciences, Inc. (TYRA) reported initial results from its Phase 2 SURF302 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC).
- BNK Invest · Sep 4, 3:50 PM EDTNoteworthy Friday Option Activity: TYRA, CLYM, AVBPAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Tyra Biosciences Inc (Symbol: TYRA), where a total of 7,130 contracts have traded so far, representing approximately 713,000 underlying shares. That amounts to about 160
- Fintel · May 19, 8:04 PM EDTWolfe Research Initiates Coverage of Tyra Biosciences (TYRA) with Peer Perform RecommendationFintel reports that on May 19, 2026, Wolfe Research initiated coverage of Tyra Biosciences (NasdaqGS:TYRA) with a Peer Perform recommendation. Analyst Price Forecast Suggests 52.23% Upside
- The Motley Fool · May 17, 3:01 PM EDTTyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More SharesHighVista increased its Tyra Biosciences holding by 96,218 shares in the first quarter; the estimated trade size was $3.11 million (based on quarterly average prices).
- Fintel · Apr 15, 8:04 PM EDTGuggenheim Initiates Coverage of Tyra Biosciences (TYRA) with Buy RecommendationFintel reports that on April 15, 2026, Guggenheim initiated coverage of Tyra Biosciences (NasdaqGS:TYRA) with a Buy recommendation. Analyst Price Forecast Suggests 44.60% Upside
- Fintel · Apr 6, 8:03 PM EDTCanaccord Genuity Initiates Coverage of Tyra Biosciences (TYRA) with Buy RecommendationFintel reports that on April 6, 2026, Canaccord Genuity initiated coverage of Tyra Biosciences (NasdaqGS:TYRA) with a Buy recommendation. Analyst Price Forecast Suggests 28.76% Upside
- The Motley Fool · Mar 20, 12:21 PM EDTThis Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New PositionBoone Capital added 398,482 shares of TYRA in the fourth quarter.
- Fintel · Feb 25, 7:25 PM ESTTyra Biosciences (TYRA) Price Target Increased by 14.97% to 48.96The average one-year price target for Tyra Biosciences (NasdaqGS:TYRA) has been revised to $48.96 / share. This is an increase of 14.97% from the prior estimate of $42.58 dated February 1, 2026. The price target is an average of many targets provided by analys
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Tyra Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.